title: Glucocorticoid-remediable aldosteronism and pregnancy.
abstract: Glucocorticoid-remediable aldosteronism (GRA) is a hereditary form of primary hyperaldosteronism that presents with hypokalemia and hypertension from childhood onward. GRA is characterized by the ectopic production of aldosterone in the cortisol-producing zona fasciculata under the regulation of adrenocorticotrophic hormone. Despite the early age of onset, no previous reports of pregnancy and GRA exist. Therefore, we set out to describe the maternal and fetal outcomes of pregnancy in women with GRA. Data regarding the blood pressure and pregnancy outcomes were collected in a retrospective chart review of prenatal and hospital records of 35 pregnancies in 16 women with genetically proven GRA. A total of 6% of pregnancies in women with GRA (GRA+) were complicated by preeclampsia. The published rates of preeclampsia in general obstetric populations vary from 2.5% to 10%. Despite the lack of an apparent increase in the rate of preeclampsia, GRA+ women with chronic hypertension had a high rate (39%) of pregnancy-aggravated hypertension. Starting with a higher baseline blood pressure, maternal blood pressure plotted over the time course of pregnancy followed a quadratic curve similar to that previously described in normal pregnancy. Mean gestational age at delivery was 39.1 weeks. Mean birth weight, excluding the 3 sets of twins, was 3219 g. However, infants of GRA+ mothers with pregnancy-aggravated hypertension tended to have lower birth weights than those that did not (3019 g versus 3385 g, respectively; P=0.08). The primary cesarean section rate was 32%, which is approximately double that seen in other general or hypertensive obstetric populations. In summary, GRA+ women did not seem to have an increased risk of preeclampsia. However, GRA+ women with chronic hypertension seem to be at an increased risk for an exacerbation of their hypertension during pregnancy.
authors.affiliation: Endocrine Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Wyckoff
authors.forename: E W
authors.initials: EW
authors.lastname: Seely
authors.forename: S
authors.initials: S
authors.lastname: Hurwitz
authors.forename: B F
authors.initials: BF
authors.lastname: Anderson
authors.forename: R P
authors.initials: RP
authors.lastname: Lifton
authors.forename: R G
authors.initials: RG
authors.lastname: Dluhy
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001724:Birth Weight / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D001835:Body Weight / Q000502:physiology; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000235:genetics / Q000503:physiopathology*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007231:Infant, Newborn; D011225:Pre-Eclampsia / Q000150:complications / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D000959:Antihypertensive Agents